Vaccination doesn’t increase risk of pediatric MS, study finds
Vaccination does not increase the risk of multiple sclerosis (MS) in children and adolescents within five years, a study…
Articles by Margarida Maia, PhD
Cannabinoids seen to ease MS spasticity, meta-analysis finds
Nabiximols and other cannabis-based preparations sometimes used with multiple sclerosis (MS) appear to work well for controlling spasticity,…
HSCT in MS challenging; patients need multidisciplinary care: Study
People with multiple sclerosis (MS) who undergo an autologous hematopoietic stem cell transplant (HSCT) — which uses a…
FDA clears upgraded software to aid MRI analysis in MS
The U.S. Food and Drug Administration (FDA) has cleared an extended version of Neurophet Aqua, an MRI analysis software that…
Most Tysabri patients see no disease activity after 6 years: Study
A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting…
Urinary tract infection is top reason for hospital admissions in MS
People with multiple sclerosis (MS) are primarily admitted to the hospital due to urinary tract infections, which indicates that…
National MS Society grant aims to make astrocytes supportive again
Backed by a $1 million grant, researchers at Case Western Reserve University in Ohio will explore ways to keep astrocytes…
National MS Society awards $4.6M to 5 projects on repairing myelin
The National Multiple Sclerosis Society is awarding a total of $4.6 million in funding to advance research into how…
Adherence to PoNS device key to improving walking in MS: Study
People with multiple sclerosis (MS) who better adhere to an at-home therapy regimen with the PoNS device —…
MS nursing scholarship fund granted $100K by EMD Serono
The Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC) has received a $100,000 donation from EMD Serono,…
Ocrevus, rituximab may not slow disability progression in PPMS
Anti-CD20 therapies like Ocrevus (ocrelizumab) and rituximab appear to be ineffective at slowing disability progression in people with…
ECTRIMS 2024: McDonald criteria changes could speed diagnoses
A revised version of the McDonald criteria, a set of guidelines used to diagnose multiple sclerosis (MS), is…
ECTRIMS 2024: Simvastatin fails to slow disability progression in SPMS
Daily treatment with high-dose simvastatin, a widely used cholesterol-lowering medication, failed to slow disability progression in adults with…
ECTRIMS 2024: High-dose vitamin D can help delay progression to MS
Taking high-dose cholecalciferol (vitamin D) as a supplement is safe and can nearly double the time it takes for people…
ECTRIMS 2024: Mavenclad sustains benefits in relapsing MS
A short course of treatment with Mavenclad (cladribine) can provide long-term reductions in disease activity and disability progression for…
Tibial nerve stimulation may ease sexual dysfunction related to MS
Transcutaneous tibial nerve stimulation (TTNS), wherein mild electrical impulses are applied to the tibial nerve located near the ankle, may…
Higher infection risk, less disability worsening with rituximab in MS
Rituximab, which is sometimes used off-label for multiple sclerosis (MS), doubles the risk of hospital-treated infections, but may…
MS patients less likely to have Alzheimer’s, study finds
People with multiple sclerosis (MS) are about half as likely as those without the disease to have signs of…
Methylphenidate may help with eye movement, processing speed in MS
Methylphenidate, a stimulant sometimes used to manage fatigue in multiple sclerosis (MS), may also ease oculomotor (eye movement) symptoms…
Can Do MS aims to help newly diagnosed patients ‘Take Charge’
Can Do Multiple Sclerosis is putting together a two-day program to help newly or recently diagnosed patients and their…
Frexalimab reduces blood NfL levels over 1 year in Phase 2 MS study
Nearly one year of treatment with frexalimab, an antibody being developed by Sanofi, significantly reduced the blood levels of…
Nykode’s inverse vaccines ease disease severity in MS mouse model
Two inverse vaccines from Nykode Therapeutics — developed to teach the immune system not to respond against its own…
Siemens Healthineers gets EU CE mark for NfL blood test for MS
Siemens Healthineers has received the CE mark in Europe for a lab-based blood test that measures the levels of…
Studies to test Briumvi in pregnant, breastfeeding MS patients
TG Therapeutics is conducting two post-marketing studies to determine how safe Briumvi (ublituximab-xiiy) is among people with relapsing forms…
Cionic’s Neural Sleeve counters foot drop in small MS study
The Neural Sleeve developed by Cionic significantly reduced foot drop, which is a difficulty lifting the foot that…
Wayne State professor wins grant to study oligodendrocytes in MS
Alexander Gow, PhD, a professor at Wayne State University School of Medicine in Detroit, has been awarded a grant to…
Employment, income drop steadily over 2 decades after onset of MS
For people who develop multiple sclerosis (MS), the disease can exact a toll on their ability to work and…
Having MS may marginally increase likelihood of cervical cancer: Study
There’s no evidence to suggest that multiple sclerosis (MS) directly causes most cancers, but having the condition may marginally…
AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical…
Viatris launches low-dose Copaxone generic formulation in Canada
Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of…